Navigation Links
Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
Date:2/1/2012

Drug Delivery Partnerships Industry Achievement Award."

As the leader in the design, delivery, manufacture and development of peptide-based therapeutics Unigene is focused on advancing its own pipeline of novel, proprietary peptide product candidates focused on metabolic disease and inflammation as well as exploiting its industry-leading Peptelligence™ platform of peptide oral drug delivery and manufacturing assets, expertise and capabilities by building a robust portfolio of strategically partnered opportunities.

"We are very proud to have Unigene as the 2012 DDP Innovation Award recipient," remarked Heather King, Program Director, Drug Delivery Partnerships. "Based upon voter response, it is clear that Unigene has cemented itself as a true innovator in oral peptide delivery and, more broadly, throughout the drug development and delivery industry."

Palmer concluded, "Unigene is proud of what it has accomplished thus far, and we are very excited by the tremendous opportunities on our horizon. We are committed to extending our leadership position and continue to firmly establish Unigene as the peptide development partner-of-choice for pharmaceutical companies interested in capitalizing on the significant opportunities that orally delivered peptides offer in the treatment of numerous debilitating diseases.  Our goal is to continue to maximize our oral peptide development expertise, depth of technological know-how and intellectual property housed within our Peptelligence™ platform."

About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and develo
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
2. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
3. Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
4. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
5. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Dr. Pollard Brings the Highest Level of Clinical ... Feb. 1 Genetic,Immunity(R), a US/Hungarian clinical-stage biopharmaceutical ... patented,immunotherapeutic platform technology, announced that it has appointed,Richard ... Dr. Pollard has been a leader in HIV/AIDS ...
... N.J., Feb. 1 Amicus Therapeutics,Inc. (Nasdaq: FOLD ... Executive Officer, will present a corporate update at the ... York, NY on Thursday, February 7, 2008 at 11:40 ... The presentation will be webcast live and may be ...
... 31 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... of common stock at a price of $27.00,per share. ... The underwriters,have an option to purchase up to an ... is expected to close on February 6,2008, subject to ...
Cached Biology Technology:Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 2Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 3Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 3Rigel Announces Pricing of Public Offering of Common Stock 2
(Date:4/17/2014)... Razzari of the nergie Matriaux Tlcommunications Research Centre ... John R. Evans Leaders Fund of the Canada ... state-of-the-art biotech and nanophotonics equipment. To this funding ... de l,Enseignement suprieur, de la Recherche, de la ... laboratories will help us develop new approaches for ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... PHILADELPHIA -- Scientists are another step closer to ... there are factors inside tumors that can slow their ... Cancer Research , a journal of the American Association ... researcher at the division of experimental medicine at the ...
... A recent study led by researchers at Boston University School ... mortality among patients diagnosed with severe sepsis and new-onset atrial ... assistant professor of medicine at BUSM and a pulmonologist at ... study, which will be published in the Journal of the ...
... SAN FRANCISCO Combining the investigational agents REGN910 ... effects in animal models compared with either agent ... International Conference: Molecular Targets and Cancer Therapeutics, held ... findings suggest that combining REGN910 (SAR307746) and aflibercept ...
Cached Biology News:BUSM: Severe sepsis, new-onset AF associated with increased risk of hospital stroke, death 2Combination therapy shows potent tumor growth inhibition in preclinical studies 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: